tbuckley/cabot-search huggingface dataset:
Reduced Leaflet Motion after Transcatheter Aortic-Valve Replacement
Authors: Ole De Backer, George D. Dangas, Hasan Jilaihawi, Jonathon A. Leipsic, Christian J. Terkelsen, Raj Makkar, Annapoorna S. Kini, Karsten T. Veien, Mohamed Abdel-Wahab, Won-Keun Kim, Prakash Balan, Nicolas Van Mieghem, Ole N. Mathiassen, Raban V. Jeger, Martin Arnold, Roxana Mehran, Ana H.C. Guimarães, Bjarne L. Nørgaard, Klaus F. Kofoed, Philipp Blanke, Stephan Windecker, Lars Søndergaard
Journal: New England Journal of Medicine (2019)

Subclinical leaflet thickening and reduced leaflet motion of bioprosthetic aortic valves have been documented by four-dimensional computed tomography (CT). Whether anticoagulation can reduce these phenomena after transcatheter aortic-valve replacement (TAVR) is not known.
The early achievement of measurable residual disease negativity in the treatment of adults with Philadelphia‐negative B‐cell acute lymphoblastic leukemia is a strong predictor for survival
Authors: Musa Yilmaz, Hagop Kantarjian, Xuemei Wang, Joseph D. Khoury, Farhad Ravandi, Jeffrey Jorgensen, Nicholas J. Short, Sanam Loghavi, Jorge Cortes, Guillermo Garcia‐Manero, Tapan Kadia, Koji Sasaki, Marina Konopleva, Koichi Takahashi, William Wierda, Nitin Jain, Srdan Verstovsek, Zeev Estrov, Prithviraj Bose, Sherry Pierce, Rebecca Garris, Susan O'Brien, Elias Jabbour
Journal: American Journal of Hematology (2019)

The minimal or measurable residual disease (MRD) status following induction/consolidation chemotherapy is an important prognostic endpoint in adult patients with newly diagnosed acute lymphoblastic leukemia (ALL). However, the optimal time-point (TP) of MRD assessment and its impact on outcome remains unclear. We analyzed 215 patients with newly diagnosed Philadelphia negative B-cell ALL who received intensive chemotherapy, and had available MRD assessment by multicolor flow cytometry at two separate TPs. The median time to first TP (1TP) and second TP (2TP) were 24 and 110 days, respectively. At 1TP, 148 patients (68%) were MRD negative and 67 (32%) were positive. Of the 148 patients with negative MRD at 1TP, 147 (99%) maintained it through 2TP. Patients who were MRD negative at both TPs, early MRD responders, had the 3-year event-free survival (EFS), and overall survival (OS) rates of 65% and 76%, respectively. Patients with improved MRD status from positive to negative, late MRD responders, had lower 3-year EFS and OS rates, 42% and 58%, respectively (P = .001). Multivariate analysis showed that KMT2A (MLL) rearrangement and MRD positivity at 1TP were the only factors correlated with worse OS. In conclusion, the earlier achievement of MRD negative remission is a stronger prognostic factor for survival.
Translational Analysis from CARTITUDE-1, an Ongoing Phase 1b/2 Study of JNJ-4528 BCMA-targeted CAR-T Cell Therapy in Relapsed and/or Refractory Multiple Myeloma (R/R MM), Indicates Preferential Expansion of CD8+ T Cell Central Memory Cell Subset
Authors: Enrique Zudaire, Deepu Madduri, Saad Z. Usmani, Andrzej Jakubowiak, Jesus G. Berdeja, Dong Geng, Syed Rizvi, Tonia Nesheiwat, Jordan M Schecter, Jenna D. Goldberg, Arnob Banerjee, Alicia J. Allred, Indrajeet Singh, Raluca Verona, Ian McCaffery, Sundar Jagannath
Journal: Blood (2019)
A Retrospective Analysis about Frequency of Monitoring in Italian Chronic Myeloid Leukemia Patients after Discontinuation
Authors: Matteo Emidio Dragani, Giovanna Rege Cambrin, Paola Berchialla, Irene Dogliotti, Gianantonio Rosti, Fausto Castagnetti, Isabella Capodanno, Marco Cerrano, Dario Ferrero, Monica Crugnola, Chiara Elena, Massimo Breccia, Alessandra Iurlo, Daniele Cattaneo, Sara Galimberti, Antonella Gozzini, Monica Bocchia, Francesca Lunghi, Michele Cedrone, Nicola Sgherza, Luigia Luciano, Sabina Russo, Marco Santoro, Valentina Giai, Giovanni Caocci, Luciano Levato, Elisabetta Abruzzese, Federica Sora, Giuseppe Saglio, Carmen Fava
Journal: Blood (2019)
ACTR-14. A PROSPECTIVE RANDOMIZED STUDY OF CONCURRENT CHEMORADIOTHERAPY WITH TEMOZOLOMIDE VERSUS RADIOTHERAPY ALONE IN PATIENTS WITH IDH WILD-TYPE/TERT PROMOTER MUTATION GRADE II/III GLIOMAS
Authors: Yanwei Liu, Xia Shan, Xiaoguang Qiu
Journal: Neuro-Oncology (2019)

Abstract Our previous data showed that WHO grade II/III gliomas with isocitrate dehydrogenase wide-type (IDH-wt) and telomerase reverse transcriptase promoter mutation (TERTp-mut) have dismal prognosis as glioblastoma. This study compared concurrent chemoradiotherapy(CRT) with radiotherapy(RT) alone on the outcome of these patients. Between September 2016 and November 2018, 30 eligible grade II/III glioma patients with IDH-wt and TERTp-mut were randomly assigned to receive either RT (60 Gy in 30 daily fractions for 6 weeks) alone (n=15) or concurrent CRT with daily temozolomide and adjuvant temozolomide (n=15). The median follow-up duration was 15.5 months. The median age was 51 years (range, 24–66 years). The median Karnofsky performance status (KPS) score at randomization was 80 (range, 60–80). Surgery was the primary treatment. The characteristics of the two treatment groups were well balanced at baseline. The 1-year OS rate was significant difference between CRT group (92.3%; 95% CI: 77.8–100) and RT alone group(71.1%; 95% CI: 47.0–95.2) (p = 0.019). Local, distant, and combined tumor recurrence patterns were observed in 4 (26.7%), 1 (6.7%), and 3 patients (20%) in the CRT group and 4 (26.7%), 3 (20%), and 3 patients (20%) in the RT alone group. Those treated with RT alone had shorter median PFS (9 vs 18 months, HR: 0.517; 95% CI: 0.193 to 1.386; p = 0.19). CRT with temozolomide and extent of resection were statistically significant predictors for survival on univariate analysis. Multivariate analysis showed that CRT was associated with a significantly better OS compared with RT alone (OR=0.195; 95% CI, 0.044 to 0.867; p=0.032). Consequently, concurrent CRT with daily temozolomide and adjuvant temozolomide for newly diagnosed IDHwt/TERTp-mut grade II/III gliomas had significantly better OS compared with RT alone. A large multi-center prospective randomized trial is warranted. The trial has been registered at ClinicalTrials.gov (NCT02766270).
Biomarkers of Hemostatic Activation and Inflammation Are Associated with Altered Coagulation Parameters in Sepsis Patients
Authors: Emily Bontekoe, Matthew T. Rondina, Debra Hoppensteadt, Elizabeth Middleton, Antoinette Blair, Fakiha Siddiqui, Divya Joshi, Alyssandra Abrenica, Iman Darwish, Maryanne Amour, Jawed Fareed
Journal: Blood (2019)
An Analysis from the WM UK Rory Morrison Registry: Waldenström's Macroglobulinaemia Patient Demographics, Disease Characteristics and Evolving Treatment Choices
Authors: Oliver Tomkins, Joshua Bomsztyk, Helen McCarthy, Jaimal Kothari, Dima El-Sharkawi, Charalampia Kyriakou, Guy Pratt, Ali Rismani, Shirley D'Sa
Journal: Blood (2019)
Effect of Electronic Health Record–Based Coaching on Weight Maintenance
Authors: Molly B. Conroy, Kathleen M. McTigue, Cindy L. Bryce, Dana Tudorascu, Bethany Barone Gibbs, Jonathan Arnold, Diane Comer, Rachel Hess, Kimberly Huber, Laurey R. Simkin-Silverman, Gary S. Fischer
Journal: Annals of Internal Medicine (2019)

Background: Weight regain after intentional loss is common. Most evidence-based weight management programs focus on short-term loss rather than long-term maintenance. Objective: To evaluate the benefit of coaching in an electronic health record (EHR)–based weight maintenance intervention. Design: Randomized controlled trial. (ClinicalTrials.gov: NCT01946191) Setting: Practices affiliated with an academic medical center. Participants: Adult outpatients with body mass index (BMI) of 25 kg/m2 or higher, intentional weight loss of at least 5% in the previous 2 years, and no bariatric procedures in the previous 5 years. Intervention: Participants were randomly assigned to EHR tools (tracking group) versus EHR tools plus coaching (coaching group). The EHR tools included weight, diet, and physical activity tracking flow sheets; standardized surveys; and reminders. The coaching group received 24 months of personalized coaching through the EHR patient portal, with 24 scheduled contacts. Measurements: The primary outcome was weight change at 24 months. Secondary outcomes included 5% weight loss maintenance and changes in BMI, waist circumference, number of steps per day, health-related quality of life, physical function, blood pressure, and satisfaction. Results: Among 194 randomly assigned participants (mean age, 53.4 years [SD, 12.2]; 143 [74%] women; 171 [88%] white), 157 (81%) completed the trial. Mean baseline weight and BMI were 85.8 kg (SD, 19.1) and 30.4 kg/m2 (SD, 5.9). At 24 months, mean weight regain (± SE) was 2.1 ± 0.62 kg and 4.9 ± 0.63 kg in the coaching and tracking groups, respectively. The between-group difference in weight change at 24 months was significant (−2.86 kg [95% CI, −4.60 to −1.11 kg]) in the linear mixed model. At 24 months, 65% of participants in the coaching group and 50% in the tracking group maintained weight loss of at least 5%. Limitation: Single-site trial, which limits generalizability. Conclusion: Among adults with intentional weight loss of at least 5%, use of EHR tools plus coaching resulted in less weight regain than EHR tools alone. Primary Funding Source: Agency for Healthcare Research and Quality and National Institutes of Health.
The Hidradenitis Suppurativa Quality of Life (HiSQOL) score: development and validation of a measure for clinical trials
Authors: J.S. Kirby, L. Thorlacius, B. Villumsen, J.R. Ingram, A. Garg, K.B. Christensen, M. Butt, S. Esmann, J. Tan, G.B.E. Jemec
Journal: British Journal of Dermatology (2019)

Hidradenitis suppurativa (HS) is a chronic, inflammatory condition that can have a large negative impact on health-related quality of life (HRQOL). A reliable and validated measure of HS-specific HRQOL in clinical studies is needed.
KTE-X19, an Anti-CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy, in Patients (Pts) With Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL): Results of the Phase 2 ZUMA-2 Study
Authors: Michael L. Wang, Javier Munoz, Andre Goy, Frederick L. Locke, Caron A. Jacobson, Brian T. Hill, John M. Timmerman, Houston Holmes, Samantha Jaglowski, Ian W. Flinn, Peter A. McSweeney, David B. Miklos, John M. Pagel, Marie Jose Kersten, Weimin Peng, Lianqing Zheng, John M. Rossi, Rajul K. Jain, Arati V. Rao, Patrick M Reagan
Journal: Blood (2019)
GATA2 Zinc Finger Mutations Influence Erythroid Differentiation and Chemotherapy Response
Authors: Georg Leubolt, Enric Redondo Monte, Anja Wilding, Paul Kerbs, Monica Cusan, Johannes Bagnoli, Wolfgang Enard, Wolfgang Hiddemann, Christian Wichmann, Gunnar Schotta, Philipp A. Greif
Journal: Blood (2019)
Volvulus of the Small Intestine
Authors: A. J. Hobson
Journal: BMJ (1950)

intubation is necessary or desirable C10 facilitates the passage of a Magill intratracheal tube without producing complete abdominal relaxation, which is so often unnecessary in E.N.T., orthopaedic, and other classes of operation.It may be used in conjunction with D-tubocurarine chloride to produce short-term relaxation of the abdominal muscles when the peritoneum is being closed and it is undesirable to give another dose of D-tubocurarine chloride because of its long action and cumulative effect.Full respiratory excursions will then be established before the patient returns to the ward.Antagonist.-Pentamethonium iodide, or C5, is the antidote to CIO.Hewer et al. (1949) have reported its effects.It acts by producing a block of the autonomic ganglia, and would seem to be contraindicated in major surgery.It may produce a profound fall in blood pres- sure, and the patient may collapse in a very alarming manner.No opportunity has arisen and no attempt been made to use this substance here.
NIMG-03. PROSPECTIVE PHASE II RANDOMIZED TRIAL COMPARING PROTON THERAPY VS. PHOTON IMRT FOR GBM: SECONDARY ANALYSIS COMPARISON OF PROGRESSION FREE SURVIVAL BETWEEN RANO VS. CLINICAL AND RADIOLOGICAL ASSESSMENT
Authors: Karine Al Feghali, James Randall, Jeffrey Wefel, Nandita Guha-Thakurta, David Grosshans, Seyedeh Dibaj, Sarah McAvoy, Jing Li, Susan McGovern, Mary McAleer, Amol Ghia, Arnold Paulino, Erik Sulman, Marta Penas-Prado, Jihong Wang, John DeGroot, Amy Heimberger, Terri Armstrong, Mark Gilbert, Anita Mahajan, Paul Brown, Caroline Chung
Journal: Neuro-Oncology (2019)

Abstract PURPOSE To compare tumor progression based on clinical radiological assessment and on Response Assessment in Neuro-Oncology (RANO) criteria between GBM patients treated with proton radiotherapy (PT) vs. photon intensity modulated radiotherapy (IMRT). METHODS Eligible patients were enrolled on the described prospective phase II trial and had MR imaging at baseline and follow-up beyond 12 weeks from treatment completion. ‘Clinical’ progression was based on a radiology report of progression in combination with changes in treatment due to suspected disease progression. A single blinded observer applied RANO criteria to determine the RANO-based tumor progression. RESULTS Of 90 enrolled patients, 66 were evaluable, with median follow-up of 19.8 (Range: 3.2–65.1) months; median of 22.6 months for PT (n=25) vs. 18.9 months for IMRT (n=41). Median time to progression (TTP) was 7.9 months based on clinical progression criteria (8.1 months IMRT, 6.3 months PT) and 7.2 months (7.3 months IMRT, 5.7 months PT) by RANO criteria (p=ns for all). Median ‘clinical’ progression-free survival (PFS) was 8.7 (Range: 6.4–11.1) months; 8.9 months IMRT vs. 8.7 months PT (p=0.065). Median RANO PFS was 8.3 (range, 5.8–11.6) months: 8.3 months IMRT vs. 6.9 months PT (p=0.226). There were 14 discrepant cases: 3 had progression based on ‘clinical’ but not RANO criteria, and 11 had progression based on RANO but not ‘clinical’ criteria. CONCLUSION Based on this secondary analysis of a randomized trial of PT vs. IMRT for GBM, there was no difference in tumor progression relative to treatment technique used. There was no statistical difference in PFS noted between clinical and RANO-based assessments, but RANO criteria identified progression more often than clinical assessment, and TTP was shortened with the use of RANO criteria alone. Further development of tumor assessment tools that improve consistency and accuracy of determining tumor progression are needed to guide therapeutic trials in GBM.
Upregulation of Senescent/Exhausted Phenotype of CAR T Cells and Induction of Both Treg and Myeloid Suppressive Cells Correlate with Reduced Response to CAR T Cell Therapy in Relapsed/Refractory B Cell Malignancies
Authors: Katia Beider, Michal J Besser, Jacob Schachter, Ania Hava Grushchenko-Polaq, Valeria Voevoda, Idit Wolf, Olga Ostrovsky, Elad Jacoby, Avichai Shimoni, Arnon Nagler
Journal: Blood (2019)
Application of a Standardized Flow Cytometry Panel for Defining and Monitoring the Immunophenotype of CAR-T Cells
Authors: Irene Scarfò, Kathleen Gallagher, Marcela V. Maus, Rebecca Larson, Maegan Sheehan, Gabrielle Brini, Scott Bornheimer, Mary Beth Hanley, Matthew Frigault, Mark Leick, Alena Chekmasova
Journal: Blood (2019)
Wound-closure with Adhesive Tape
Authors: R. J. Sellick
Journal: BMJ (1964)

MEDILlHdue to neuromuscular block of respiratory muscles, since they could have completely recovered.With the existing knowledge, could I suggest another explanation of the events in the case reported by Dr. Ross and his colleagues ?The presence of curare-like block on E.M.G. could be due to recurarization as a result of 180 mg. of gallamine, used in a patient with poor circulation, poor renal function, and a very low serum calcium level.The respiratory inadequacy at the end of operation in spite of 2.5 mg. of neostigmine could be attributed to the existence of metabolic acidosis, maintained and accentuated by superadded respiratory acidosis with or without partial recurarization.Oral neomycin has a distinct advantage of its own in the prevention of complications after elective surgery on the colon ; therefore, before surgeons can accept the suggestion that "neomycin should be kept to a minimum" more convincing proof is required.-Iam, etc.,
Exercise reduces inflammatory cell production and cardiovascular inflammation via instruction of hematopoietic progenitor cells
Authors: Vanessa Frodermann, David Rohde, Gabriel Courties, Nicolas Severe, Maximilian J. Schloss, Hajera Amatullah, Cameron S. McAlpine, Sebastian Cremer, Friedrich F. Hoyer, Fei Ji, Ian D. van Koeverden, Fanny Herisson, Lisa Honold, Gustavo Santos Masson, Shuang Zhang, Jana Grune, Yoshiko Iwamoto, Stephen P. Schmidt, Gregory R. Wojtkiewicz, I-Hsiu Lee, Karin Gustafsson, Gerard Pasterkamp, Saskia C. A. de Jager, Ruslan I. Sadreyev, Jean MacFadyen, Peter Libby, Paul Ridker, David T. Scadden, Kamila Naxerova, Kate L. Jeffrey, Filip K. Swirski, Matthias Nahrendorf
Journal: Nature Medicine (2019)
Targeting redox heterogeneity to counteract drug tolerance in replicating <i>Mycobacterium tuberculosis</i>
Authors: Richa Mishra, Sakshi Kohli, Nitish Malhotra, Parijat Bandyopadhyay, Mansi Mehta, MohamedHusen Munshi, Vasista Adiga, Vijay Kamal Ahuja, Radha K. Shandil, Raju S. Rajmani, Aswin Sai Narain Seshasayee, Amit Singh
Journal: Science Translational Medicine (2019)

Chloroquine resets the redox physiology of Mycobacterium tuberculosis to potentiate the efficacy of antibiotics in vivo.
CoA Synthase (<i>COASY</i>) Mediates Radiation Resistance via PI3K Signaling in Rectal Cancer
Authors: Sylvain Ferrandon, Jennifer DeVecchio, Leonardo Duraes, Hanumant Chouhan, Georgios Karagkounis, Jacqueline Davenport, Matthew Orloff, David Liska, Matthew F. Kalady
Journal: Cancer Research (2019)

Abstract Neoadjuvant radiation is standard of care for locally advanced rectal cancer. Response to radiation is highly variable and directly linked with survival. However, there currently are no validated biomarkers or molecular targets to predict or improve radiation response, which would help develop personalized treatment and ideally targeted therapies. Here, we identified a novel biomarker, coenzyme A synthase (COASY), whose mRNA expression was consistently elevated in radioresistant human rectal cancers. This observation was validated in independent patient cohorts and further confirmed in colorectal cancer cell lines. Importantly, genetic overexpression and knockdown yielded radioresistant and sensitive phenotypes, respectively, in vitro and in vivo. COASY-knockdown xenografts were more vulnerable to radiation, showing delayed tumor growth, decreased proliferation, and increased apoptosis. Mechanistically, COASY protein directly interacted with the PI3K regulatory subunit PI3K-P85α, which increased AKT and mTOR phosphorylation, enhancing cell survival. Furthermore, shRNA COASY knockdown disrupted downstream PI3K pathway activation and also hindered DNA double-strand break repair, which both led to improved radiosensitivity. Collectively, this work reveals for the first time the biological relevance of COASY as a predictive rectal cancer biomarker for radiation response and offers mechanistic evidence to support COASY as a potential therapeutic target. Significance: COASY is a novel radiotherapy response modulator in rectal cancer that regulates PI3K activation and DNA repair. Furthermore, COASY levels directly correlate with radiation response and serve as a predictive biomarker.
Intra-partum Uterine Rupture
Authors: H. J. Knight
Journal: BMJ (1953)

MEDICAL JOURNL coccal food-poisoning; what evidence we found is negative rather than positive.Nevertheless it would seem that staphylococcal food-poisoning is the commonest cause of the frequent mild cases of diarrhoea, with or without vomiting, met with in general practice. SummaryNinety unselected cases of acute gastro-enteritis, occurring over a period of nine months in an urban practice, were investigated.In by far the greatest number of these no pathogenic organisms were found.The commonest specific organism isolated was Sh. sonnei.Pr. vulgaris was the next most common.Only one case of infection with Salm.typhi-murium was found.One case was subsequently diagnosed in hospital as food-poisoning (toxin type).Arguments are advanced for the belief that staphylo- coccal food-poisoning is the commonest cause of mild cases of gastro-enteritis.even with a child in a good obstetric position.
Syndecan-1 Is Critical in ARF6-Dependent Macropinocytosis Driven By KRAS Mutation in the Pathophysiology of Multiple Myeloma
Authors: Tengteng Yu, Liang Lin, Kenneth Wen, Lijie Xing, Jiye Liu, Shih-Feng Cho, Phillip Hsieh, Ola Rizq, Yuyin Li, Liang Yu, Xiang Wu, Eugenio Morelli, Yan Xu, Gang An, Nikhil C. Munshi, Lugui Qiu, Kenneth C. Anderson, Yu-Tzu Tai
Journal: Blood (2019)
Lenalidomide and Rituximab (ReRi) As Front Line Chemo-Free Therapy of Elderly Frail Patients with Diffuse Large B-Cells Lymphoma. a Phase II Study of the Fondazione Italiana Linfomi (FIL)
Authors: Guido Gini, Monica Tani, Alessandra Tucci, Renato Bassan, Filippo Ballerini, Michela Sampaolo, Francesco Merli, Francesca Re, Attilio Olivieri, Ombretta Annibali, Anna Marina Liberati, Carlo Visco, Annalisa Arcari, Sergio Storti, Alberto Fabbri, Gerardo Musuraca, Vittorio Ruggero Zilioli, M. Christina Cox, Stefano Luminari
Journal: Blood (2019)
Mouse Erythroid Cells Originate from a Megakaryocyte Precursor in Common Myeloid Progenitors
Authors: Elisabeth F Heuston, Bethan Psaila, Cheryl A Keller, NISC Comparative SequencingProgram, Stacie M Anderson, Martha Kirby, Lauren C Murphy, Alexander Q Wixom, Belinda Giardine, Ross C. Hardison, David M. Bodine
Journal: Blood (2019)
EPID-17. ANALYSIS OF THE USE OF BEVACIZUMAB FOR THE TREATMENT OF GLIOBLASTOMA IN THE UNITED STATES
Authors: Catherine Garcia, Holly Chitwood, Christopher Harwood, Brent Shelton, Rachael Morgan, Lee Vermuelen, John Villano
Journal: Neuro-Oncology (2019)

Abstract INTRODUCTION Bevacizumab is an antibody against vascular endothelial growth factor that has been well investigated for glioblastoma, however, has limited proven efficacy. The drug has, however, demonstrated survival benefit in non-small cell lung carcinoma, renal cell carcinoma and colorectal carcinoma. We provide an overview of its use in the United States for select cancers. METHODS We queried the IQVIA database for all cases of glioblastoma diagnosed between January 2014 and June 2018 to analyze the use of bevacizumab for glioblastoma, non-small cell lung carcinoma, and colorectal carcinoma in the United States, and was compared to the standard of care for each indication (temozolomide for glioblastoma, pemetrexed for non-small cell lung carcinoma, and oxaliplatin for colorectal carcinoma). RESULTS A total of 85,351 patients were treated for glioblastoma as captured by IQVIA. Bevacizumab was prescribed in 17,958 patients, with a projected median annual total of 3,718 patients. The use of bevacizumab for glioblastoma during the study period decreased from 2014 to 2018 (p&lt; 0.0001). The use of temozolomide has remained stable since 2014 to 2018 (p=0.49). For non-small cell lung cancer, we saw a significant decrease in the use of both bevacizumab and pemetrexed (p&lt; 0.0001), with bevacizumab being used in less than 2% of the cases since 2017. For colorectal carcinoma, the use of bevacizumab has overall decreased with a peak use in 2016 (p&lt; 0.0001). The use of oxaliplatin has increased (p&lt; 0.0001). CONCLUSIONS Our findings demonstrated a decreased use of bevacizumab in oncology for three indications, likely associated with a changing role due to the benefit of novel therapy such as immunotherapy. The use of bevacizumab has decreased in glioblastoma, that may be associated to the lack of overall survival benefits in randomized clinical trials.